He is an Honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.As a prelude to specializing in cardiology, he undertook research at the University of Dundee with Allan Struthers MB who was engaged in work on recently-discovered natriuretic peptides.In 1993, he was appointed to a consultant role in Edinburgh before a Medical Research Council initiative on heart failure drew him back to Glasgow 2 years later.He received one of the two medals given out each year by the Society at their Annual Conference in June.His main research activity is clinical trials and he is, or was, the principal investigator, member of the executive committee or steering committee member in a number of large trials in his areas of interest.He has also been included in the 2014 and 2016 Highly Cited Researchers listing and one of The World's Most Influential Scientific Minds: 2014 by Thomson Reuters.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
University of Glasgow
The antidiabetic drug dapagliflozin reduces the risk of death and hospitalization in patients with heart failure with reduced ejection fraction regardless of diabetic status, the DAPA-HF trial has shown. The DAPA-HF trial recruited 4,744 HFrEF patients with or without diabetes from 20 countries. They were randomized to receive dapagliflozin 10 mg once daily or placebo, in addition to standard-of-care therapy. "Importantly, the benefits were observed regardless of T2DM status," highlighted McMurray.
In patients with heart failure, both with and without diabetes, dapagliflozin was shown to provide identical efficacy and possibly beneficial effects on the heart, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
When Professor John McMurray from the University of Glasgow presented the decidedly positive results of the Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction trial at the European Society of Cardiology Congress in Paris, it felt like a before-and-after moment in medical history. Crucially, DAPA-HF was a heart failure trial; more than half the patients did not have diabetes. Many patients with heart failure have comorbidities.